Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02207556 · OUTCOME

Mortality

Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial · Source last updated 2021-07-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline, 3 months, 6 months, 1 year

What was measured

The number of living subjects will be determined at Baseline, 3 months, 6 months and 1 year

Groups in this outcome

Doxycycline (Localized Disease)

Doxycycline will be administered at dose of 100mg orally twice daily for 1 year. Doxycycline: Doxycycline will be continued until one of the following criteria is met: * Patient has completed 1 year of doxycycline therapy * Patient develops any grade 3-4 toxicity related to doxycycline use.

Doxacycline (Systemic Disease)

Doxycycline will be administered at dose of 100mg orally twice daily for 1 year. Doxycycline: Doxycycline will be continued until one of the following criteria is met: * Patient has completed 1 year of doxycycline therapy * Patient develops any grade 3-4 toxicity related to doxycycline use.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Doxycycline (Localized Disease)6
Doxacycline (Systemic Disease)25

Reported measurements

Baseline
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Doxycycline (Localized Disease)6Not reportedNot reportedNot reportedNot reported
Doxacycline (Systemic Disease)25Not reportedNot reportedNot reportedNot reported
3 Months
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Doxycycline (Localized Disease)6Not reportedNot reportedNot reportedNot reported
Doxacycline (Systemic Disease)23Not reportedNot reportedNot reportedNot reported
6 Months
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Doxycycline (Localized Disease)6Not reportedNot reportedNot reportedNot reported
Doxacycline (Systemic Disease)22Not reportedNot reportedNot reportedNot reported
1 Year
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Doxycycline (Localized Disease)6Not reportedNot reportedNot reportedNot reported
Doxacycline (Systemic Disease)20Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        6
      2. group Id
        OG001
        value
        25
    title
    Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        6
      2. group Id
        OG001
        value
        23
    title
    3 Months
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        6
      2. group Id
        OG001
        value
        22
    title
    6 Months
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        6
      2. group Id
        OG001
        value
        20
    title
    1 Year
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    2. group Id
      OG001
      value
      25
    units
    Participants
description
The number of living subjects will be determined at Baseline, 3 months, 6 months and 1 year
groups
  1. description
    Doxycycline will be administered at dose of 100mg orally twice daily for 1 year. Doxycycline: Doxycycline will be continued until one of the following criteria is met: * Patient has completed 1 year of doxycycline therapy * Patient develops any grade 3-4 toxicity related to doxycycline use.
    id
    OG000
    title
    Doxycycline (Localized Disease)
  2. description
    Doxycycline will be administered at dose of 100mg orally twice daily for 1 year. Doxycycline: Doxycycline will be continued until one of the following criteria is met: * Patient has completed 1 year of doxycycline therapy * Patient develops any grade 3-4 toxicity related to doxycycline use.
    id
    OG001
    title
    Doxacycline (Systemic Disease)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Baseline, 3 months, 6 months, 1 year
title
Mortality
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice